Cook Medical’s Zilver® PTX® Trial Shows Sustained Patency After Three Years

LAS VEGAS--(BUSINESS WIRE)--Three-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical demonstrate 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent. This compares to 49.1 percent patency for patients with percutaneous transluminal angioplasty and provisional bare metal stent placement in the 479-patient study.